论文部分内容阅读
目的:观察α-2b型干扰素(假单胞菌)雾化吸入治疗病毒性上感儿童的临床疗效。方法:100例确诊为病毒性上呼吸道感染的患儿按就诊顺序分为观察组和对照组各50例。两组患儿均给予对症及支持治疗,观察组在此基础上给予注射用重组人干扰素α-2b(假单胞菌)15万IU·kg-1·d-1加0.9%氯化钠注射液2~4 ml雾化吸入给药,qd,每次5~10 min,对照组给予利巴韦林注射液10~15 mg·kg-1·d-1加5%葡萄糖注射液150 ml,ivd。两组均连续治疗5 d为1个疗程。比较治疗前后两组退热效果、感冒症状(包括咳嗽、卡他、全身症状)改善情况和临床有效率。结果:治疗后,观察组患儿退热疗效显著优于对照组(P<0.05);观察组患儿治疗后轻、中度咳嗽变化情况显著优于对照组(P<0.01);观察组热程、咳嗽消退时间、卡他症状消退时间和全身症状消退时间均显著优于对照组(P<0.05);观察组临床有效率达96.0%,显著高于对照组的84.0%(P<0.05)。结论:在常规治疗基础上,雾化吸入α-2b干扰素治疗病毒性上呼吸道感染患儿效果显著,安全性高,值得在临床上推广使用。
Objective: To observe the clinical efficacy of α-2b interferon (Pseudomonas aeruginosa) inhalation in the treatment of viral upper respiratory tract infection. Methods: 100 cases of children diagnosed with viral upper respiratory tract infection were divided into observation group and control group according to the order of treatment. Two groups of children were given symptomatic and supportive treatment, the observation group was given on the basis of injection of recombinant human interferon α-2b (Pseudomonas) 150,000 IU · kg-1 · d-1 plus 0.9% sodium chloride Injection of 2 ~ 4 ml atomized inhalation, qd, each 5 ~ 10 min, the control group was given ribavirin injection of 10 ~ 15 mg · kg-1 · d-1 plus 5% glucose injection 150 ml , ivd. Both groups were treated for 5 consecutive days as a course of treatment. Before and after treatment, the antipyretic effect and the improvement of cold symptom (including cough, catarrhal, systemic symptoms) and clinical efficiency were compared between the two groups. Results: After treatment, the efficacy of antipyretic in observation group was significantly better than that in control group (P <0.05). The changes of mild and moderate cough in observation group were significantly better than those in control group (P <0.01) (P <0.05). The clinical effective rate in the observation group was 96.0%, which was significantly higher than that in the control group (84.0%, P <0.05), and the regression time of cough, the regression time of catarrhal symptoms and the regression time of systemic symptoms were significantly better than those in the control group . Conclusion: On the basis of routine treatment, inhalation of interferon alfa-2b in children with viral upper respiratory tract infection has significant effect and high safety, which is worth to be popularized in clinic.